Is Pfizer a yield trap? No way.

Pfizer is looking to newer products and acquisitions to offset a declining Covid business.

By Mariam Sunny and Christy Santhosh May 5 (Reuters) - Pfizer reported higher-than-expected sales and profit on Tuesday and ...

Pfizer’s $2.3 billion bet on Trillium Therapeutics doesn’t look like it will ever pay out, with the Big Pharma abandoning the ...

By Mariam Sunny and Christy Santhosh May 5 (Reuters) - Pfizer said on Tuesday that it expects to return to stronger growth ...

Pfizer is also demonstrating that its commercial portfolio can flourish beyond the historically mammoth sales of its COVID-19 ...

Veppanu, the first PROTAC therapy approved by the FDA, improved progression free survival by 43% versus AstraZeneca’s ...

Despite the continued decline of Pfizer's COVID-19 products, shares stayed stable on Tuesday morning after the New York ...

Pharma giant is working hard to offset its post-Covid hangover but faces a patent cliff on many top-selling medicines ...

Shares of Pfizer are down 50% from their 2021 high, and the yield is an alluring 6.4%.

Pfizer's vaccine business cooled off, and it is on its back foot in the GLP-1 race, but don't count the drug giant out.

Pfizer (PFE) stock gained 0.5% premarket after Q1 EPS of $0.75 topped forecasts. Eliquis drove revenue strength as company ...